FDA grants breakthrough status to OFEV (nintedanib) forthe treatment of chronic fibrosing interstitial lung diseases (ILDs), other than idiopathic pulmonary fibrosis (which it is currently approved for). Nintedanib has been studied in PSS ILD. https://t.co/K0ZTyqrfh6